Gen-Probe, Bayer call truce on patent row
This article was originally published in Clinica
San Diego, California-based nucleic acid testing specialist Gen-Probe and Bayer Healthcare are ending their four-year legal wrangle involving multiple patent litigation and contract arbitrations with a settlement that would see the German drugs giant fork out up to $31.7m to its one-time business partner.
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
Discussions on the shape of health care have moved from “reimagining” to the next stage: building and executing on the vision. That is the thrust of EY’s NextWave Report: New Horizons 2019. Additionally, for medtechs seeking business continuum, “duality” is now a preoccupying thought.
The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.